Sarepta stock catapulted early Thursday after the biotech company made a "tough but prudent move," laying off roughly 500 employees and restructuring its business in the wake of two deaths following treatment with its gene therapy, Elevidys.
Leerink Partners analyst Joseph Schwartz…